Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

CAR T-cell therapy | Image credit: Getty Images Science Library
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

June 12th 2024

Older male patient speaking with doctor | Image credit: DragonImages - adobe.stock.com
Dr Christopher Flowers: Liso-Cel Approval for Mantle Cell Lymphoma Changes the Treatment Strategy

June 7th 2024

Breyanzi packaging | Image credit: BMS
FDA Approves Liso-Cel to Treat R/R Mantle Cell Lymphoma

May 30th 2024

Rajni Natesan, MD, MBA | Image credit: Clarified Precision Medicine
Bringing the Human Factor to the “Last Mile” of AI-Assisted Clinical Decisions

May 24th 2024

Doctor with health care icons and FDA | Image credit: wladimir1804 - stock.adobe.com
Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC

May 17th 2024

More News

Pembrolizumab Superior to Standard of Care in SCC
December 26th 2018

Pembrolizumab Superior to Standard of Care in SCC

Samantha DiGrande
A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).
FDA Grants Accelerated Approval to Pembrolizumab for MCC
December 22nd 2018

FDA Grants Accelerated Approval to Pembrolizumab for MCC

Samantha DiGrande
Earlier this week, the FDA granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Soluble CD163 Potential Biomarker in Advanced Cutaneous Melanoma
December 21st 2018

Soluble CD163 Potential Biomarker in Advanced Cutaneous Melanoma

David Bai, PharmD
Patients with advanced cutaneous melanoma who are responsive to nivolumab (Opdivo) have higher serum levels of soluble CD163 (sCD163) compared with nonresponders, according to the results of a recent study.
The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System
December 15th 2018

The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System

David Bai, PharmD
The Allen Institute for Immunology has partnered with several cancer institutions, including the Fred Hutchinson Cancer Research Center, with the primary goal of understanding the differences between a defective and healthy immune system to improve immune-based treatments.
Dr Brian Koffman Explains How PROs Can Provide Insight Into CAR T Benefits
December 12th 2018

Dr Brian Koffman Explains How PROs Can Provide Insight Into CAR T Benefits

While patient-reported outcomes don’t provide the whole story, they can provide insight into how chimeric antigen receptor (CAR) T-cell therapy changes a patient’s life, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL
December 6th 2018

Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL

Surabhi Dangi-Garimella, PhD
A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Carfilzomib-Based Combination Results in Sustained MRD-Negative Complete Response in Multiple Myeloma
December 6th 2018

Carfilzomib-Based Combination Results in Sustained MRD-Negative Complete Response in Multiple Myeloma

Jaime Rosenberg
Researchers at the 60th American Society of Hematology Annual Meeting & Exposition presented long-term study results showing that high rates of minimal residual disease–negative complete response were sustained with a median duration of over 4 years among treatment-naïve patients with multiple myeloma.
Site Logo
December 4th 2018

The Value of Novel Immuno-Oncology Treatments

John A. Romley, PhD Andrew Delgado, PharmD Jinjoo Shim, MS Katharine Batt, MD
This study assesses the value of novel immuno-oncology treatments to society.
Dr Michael Kolodziej Discusses Concerns Around Paying for Innovative Treatments, Like CAR T
December 3rd 2018

Dr Michael Kolodziej Discusses Concerns Around Paying for Innovative Treatments, Like CAR T

While new therapies like chimeric antigen receptor (CAR) T-cell therapy, can have amazing results, the innovation of these treatments has outstripped the United States’ ability to pay for them, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.
Site Logo
December 2nd 2018

Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings

Surabhi Dangi-Garimella, PhD
A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.
Larotrectinib Approved to Treat Patients With Advanced Solid Tumors Expressing NTRK
November 30th 2018

Larotrectinib Approved to Treat Patients With Advanced Solid Tumors Expressing NTRK

Samantha DiGrande
This week, the FDA approved larotrectinib, to be sold as Vitrakvi, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene infusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
CD7 CAR T Cells Selectively Target Leukemic Cells in Patients With AML
November 25th 2018

CD7 CAR T Cells Selectively Target Leukemic Cells in Patients With AML

David Bai, PharmD
CD7 gene-edited chimeric antigen receptor (CAR) T cells target CD7-positive acute myeloid leukemia (AML) cells while sparing myeloid and erythroid cells and minimizing toxicity, according to the results of a recent study.
Dr Brian Koffman Outlines the Follow-up as a Patient Treated With CAR T
November 24th 2018

Dr Brian Koffman Outlines the Follow-up as a Patient Treated With CAR T

After being treated for his chronic lymphocytic leukemia with chimeric antigen receptor (CAR) T-cell therapy, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, is being followed for 15 years to better understand if there are any undiscovered adverse events that pop up and how durable the response is.
FDA Approves Pembrolizumab to Treat HCC
November 20th 2018

FDA Approves Pembrolizumab to Treat HCC

Samantha DiGrande
Earlier this month, Merck announced that the FDA approved its anti–PD-1 therapy, pembrolizumab (sold as Keytruda), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Nivolumab Plus Azacitidine Increased Response Rates in Patients With Relapsed AML
November 16th 2018

Nivolumab Plus Azacitidine Increased Response Rates in Patients With Relapsed AML

David Bai, PharmD
The addition of nivolumab to azacitidine led to significantly better overall response rate and overall survival compared with previous hypomethylating agent-based regimens in patients with relapsed acute myeloid leukemia (AML), according to the results of a recent phase 2 study.
CD8 T Cell May Determine Patient Responses to Immune Checkpoint Inhibitors for Melanoma
November 13th 2018

CD8 T Cell May Determine Patient Responses to Immune Checkpoint Inhibitors for Melanoma

Samantha DiGrande
Researchers from Massachusetts General Hospital and the Broad institute of MIT and Harvard recently identified specific states of cytotoxic CD8+ T cells that are associated with patient response to checkpoint immunotherapy for melanoma.
Nobel Prize Winner Dr James Allison on the Impact His Work Has Made
November 12th 2018

Nobel Prize Winner Dr James Allison on the Impact His Work Has Made

It has been good knowing that treatments he has had a hand in developing will give years of quality life to patients, where treatments only gave a few months before, explained James Allison, PhD, chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, director of the Parker Institute for Cancer Research, executive director of the Immunotherapy Platform at MD Anderson Cancer Center, and 2018 Nobel Prize cowinner in Medicine.
FDA Approves New Immunotherapy Combination for Relapsed/Refractory Multiple Myeloma
November 8th 2018

FDA Approves New Immunotherapy Combination for Relapsed/Refractory Multiple Myeloma

Samantha DiGrande
Today, the FDA approved elotuzumab (Empliciti), an injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies.
Immunotherapy Improves Survival in Metastatic Melanoma
November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD
The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.
Pembrolizumab Plus Chemotherapy Approved to Treat Metastatic Squamous NSCLC
November 2nd 2018

Pembrolizumab Plus Chemotherapy Approved to Treat Metastatic Squamous NSCLC

Samantha DiGrande
Earlier this week, the FDA approved pembrolizumab (Keytruda) in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
CAR T Cells Improve Antitumor Activity in Hepatocellular Carcinoma
November 1st 2018

CAR T Cells Improve Antitumor Activity in Hepatocellular Carcinoma

David Bai, PharmD
Gene-edited glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T cells with deficient programmed death–1 have greater cytotoxicity compared with wild-type GPC3-targeted T cells in GPC3-positive hepatocellular carcinoma, based on results from a recent study.
PD-1 Inhibitors Effective in Metastatic Conjunctival Melanoma
October 27th 2018

PD-1 Inhibitors Effective in Metastatic Conjunctival Melanoma

David Bai, PharmD
A study published in JAMA Opthalmology has confirmed that PD-1 inhibitors, and nivolumab in particular, are effective in the treatment of metastatic conjunctival melanoma.
Nobel Prize Winner Dr James Allison on Meeting Patients Treated With Ipilimumab
October 24th 2018

Nobel Prize Winner Dr James Allison on Meeting Patients Treated With Ipilimumab

As a basic scientist, James Allison, PhD, didn’t always meet the patients who benefitted from treatments he discovered, but he did meet 1 woman who participated in one of the early trials of ipilimumab.
Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer
October 23rd 2018

Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer

Samantha DiGrande
A phase 3 trial recently investigated if nanoparticle albumin-bound paclitaxel enhances the treatment of atezolizumab in unresectable locally advanced or metastatic triple-negative breast cancer.
Switchable CAR T Cells May Be Safer in Pancreatic Cancer
October 19th 2018

Switchable CAR T Cells May Be Safer in Pancreatic Cancer

David Bai, PharmD
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17th 2018

Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial

Samantha DiGrande
Last week, Bristol-Myers Squibb announced results from the phase 3 CheckMate -331 trial that investigated nivolumab (Opdivo) versus the current standard of care, chemotherapy, in the treatment of patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. The trial found that nivolumab did not significantly increase overall survival compared with chemotherapy.
FDA Approves Libtayo to Treat Second Most Common Skin Cancer
October 10th 2018

FDA Approves Libtayo to Treat Second Most Common Skin Cancer

Samantha DiGrande
Last week, the FDA granted approval to immune checkpoint inhibitor cemiplimab-rwlc, to be sold as Libtayo, for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), or in patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?
October 8th 2018

Does Transcriptional Loss of HLA Cause Immunotherapy Resistance?

David Bai
The development of resistance to immunotherapy is poorly understood and is detrimental to patients who relapse on multiple lines of treatment. Transcriptional downregulation of class 1 human leukocyte antigen (HLA) may contribute to the developed resistance of immunotherapies, including checkpoint inhibitors, and warrants further investigation, according to a study published in Nature Communications.
Site Logo
October 1st 2018

Nobel Prize Recognizes Discoveries With T Cells in Immunotherapy

Mary Caffrey
James P. Allison, PhD, and Tasuku Honjo, MD, PhD, led the basic science experiments that showed the potential of checkpoint inhibitors, creating a fourth pillar in the treatment of cancer.
Single Resistant Cell Causes Case of Rare ALL Relapse After CAR T Therapy
October 1st 2018

Single Resistant Cell Causes Case of Rare ALL Relapse After CAR T Therapy

Allison Inserro
A single leukemia cell was able to reproduce and cause a deadly relapse of pediatric B-cell acute lymphoblastic leukemia (ALL) after it had bonded with the leukemia-targeting chimeric antigen receptor (CAR) lentivirus and infused back into a patient. The case of the cell that became resistant to CAR T-cell therapy was published in the journal Nature Medicine Monday.
<1
...
567891011121314>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo